Roche Goes Back To Nature With Warp Drive Antibiotic Pact
Executive Summary
The Swiss major is paying up to $387m to get access to potential natural antibiotics that have not been analyzed previously, 'owing to historical technology limitations.'
You may also be interested in...
Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions...
Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan
Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.
Polyphor Pursues Promise Of Inhaled Antibiotics To Tackle Lung Infections
An IMI-backed consortium is developing inhaled formulations of the privately held Swiss company's murepavadin and Novartis's tobramycin to reduce infections suffered by bronchiectasis and cystic fibrosis patients.